---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-011700"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:37:36.079410+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus divests CIMERLI ophthalmology franchise to Sandoz for $170M upfront cash

## Summary
- Divestiture of CIMERLI (ranibizumab-eqrn) and supporting commercial infrastructure to Sandoz.
- Total upfront cash consideration $170M plus value of CIMERLI product inventory and working capital adjustments.
- Coherus intends to use proceeds to pay down debt, reduce interest costs, and focus on oncology (UDENYCA, LOQTORZI, pipeline).
- Closing expected first half 2024, subject to HSR antitrust waiting period expiration or termination.
- Coherus reduces headcount and overhead; J.P. Morgan and Latham & Watkins advised.

## SEC filing metadata
- accession: 0001193125-24-011700
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000119312524011700/0001193125-24-011700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000119312524011700/d632519d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-011700
- JSON: https://secwatch.observer/filing/0001193125-24-011700.json
- Plain text: https://secwatch.observer/filing/0001193125-24-011700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.